Medical Cost Trends Benefit Humana Q2 Earnings, Raises FY22 Profit Outlook

  • Humana Inc HUM has posted Q2 adjusted sales of $23.72 billion, beating the consensus of $23.47 billion.
  • The benefits expense ratio remained unchanged at 85.8%, and the operating cost ratio increased from 10.3% to 12.5%. 
  • Humana posted an adjusted EPS of $8.67, beating the consensus of $7.67 and $6.89 a year ago.
  • The 26% increase resulted from better-than-anticipated medical cost trends in the company’s individual Medicare Advantage and Medicaid businesses and lower-than-anticipated administrative costs.
  • Guidance: Humana expects FY22 adjusted EPS of at least approximately $24.75, up from prior guidance of $24.50, versus the consensus of $24.63.
  • The company still maintains a $0.50 EPS COVID-19 headwind for the back half of the year.
  • The company reaffirms FY 2022 expected individual Medicare Advantage membership growth of approximately 150,000 to 200,000.
  • Price Action: HUM shares are down 1.99% at $482.50 during the premarket session on the last check Wednesday.
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!